Vial Doses First Asthma Patient with Twice-Yearly Bispecific Antibody

Vial announced today that it has dosed the first patient with asthma in a Phase 1b study of its investigational IL-13 x TSLP bispecific antibody, a therapy designed for twice-yearly (Q6M) dosing. The milestone marks the transition of the program from healthy volunteer studies into a patient population, potentially offering a new treatment option for Type 2 inflammatory diseases.

The Phase 1b trial follows Phase 1a data in healthy volunteers who received intravenous doses ranging from 15 to 800 mg. Those results demonstrated pharmacokinetics that could support twice-yearly dosing, a significant advantage over currently available biologics that typically require more frequent administration. Vial's bispecific antibody aims to deliver breadth, depth, and durability of Type 2 disease control in a single half-life-extended molecule.

If successful, this approach could simplify treatment regimens for asthma patients and improve adherence. The company has not disclosed the number of patients to be enrolled or the trial's primary endpoints. Further details are expected as the study progresses, with potential implications for the broader respiratory biologics market.